drugset / Trial / NCT01631903

Extension of Study ZPV-200

NCT01631903

Phase 2 Completed 48 enrolled Repros Therapeutics Inc.
RandomizedCrossoverSingle-blindTreatment

Summary

The purpose of this study is to determine the safety, pharmacokinetics and efficacy of four doses of vaginally administered Proellex in premenopausal women with uterine fibroids confirmed by ultrasound.

Timeline

Start
2012-09
Primary completion
2014-04
Completion
2014-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Telapristone Acetate Other / unclassified 3 mg Other
Subject Telapristone Acetate Other / unclassified 6 mg Other
Subject Telapristone Acetate Other / unclassified 12 mg Other
Subject Telapristone Acetate Other / unclassified 24 mg Other